The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
Haemonetics Corporation (NYSE:HAE)
- On Aug. 8, Haemonetics posted better-than-expected quarterly earnings. The company's stock fell around 19% over the past month and has a 52-week low of $70.74.
- RSI Value: 25.47
- HAE Price Action: Shares of Haemonetics gained 1.1% to close at $73.99 on Thursday.
- Benzinga Pro's real-time newsfeed alerted to latest HAE news.
Immunitybio Inc (NASDAQ:IBRX)
- On Aug. 6, ImmunityBio announced study of ANKTIVA in combination with the AdHER2DC cancer vaccine as a potential therapy to control endometrial cancer. The company's stock fell around 38% over the past month. It has a 52-week low of $1.25.
- RSI Value: 29.87
- IBRX Price Action: Shares of Immunitybio rose 2.6% to close at $3.98 on Thursday.
- Benzinga Pro’s charting tool helped identify the trend in IBRX stock.
Progyny Inc (NASDAQ:PGNY)
- On Aug. 6, Progyny reported worse-than-expected second-quarter revenue results. “The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healthy and within the range of our long-established patterns,” said Pete Anevski, Chief Executive Officer of Progyny. The company's shares fell around 31% over the past month and has a 52-week low of $19.60.
- RSI Value: 29.06
- PGNY Price Action: Shares of Progyny rose 1.7% to close at $20.85 on Thursday.
- Benzinga Pro’s signals feature notified of a potential breakout in PGNY shares.
Read Next:
- Jim Cramer Recommends Buying Clorox: ‘CEO Has Done Remarkable Job’
